Diffuse Large B-cell Lymphoma Recurrent Clinical Trial
Official title:
A Prospective, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of Zanubrutinib, Lenalidomide With R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
This is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05966233 -
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06086197 -
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
|
Phase 2 | |
| Recruiting |
NCT03795571 -
Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL
|
Phase 1 | |
| Completed |
NCT05169203 -
The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study
|
||
| Completed |
NCT01805557 -
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02955628 -
RICE-ibrutinib in Relapsed DLBCL
|
Phase 2 | |
| Completed |
NCT03589469 -
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
Phase 2 |